Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious Disorders)
  4. Volume 25, Issue 1
  5. Article
Volume 25, Issue 1
  • ISSN: 1871-5265
  • E-ISSN: 2212-3989

Abstract

The COVID-19 pandemic is casting a long shadow, and the appearance of the JN.1 variety calls attention to the necessity of maintaining heightened awareness. It considers the strength that has been developed immunization programs and the necessity of global collaboration to find a solution in light of the emergence of new strains of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Phylogenetically, the SARS-CoV-2 Omicron XBB lineages, which include EG.5.1 and HK.3, are different from the SARS-CoV-2 BA.2.86 lineage, which was initially discovered in August 2023. More than 30 mutations in the spike (S) protein are carried by BA.2.86 compared to XBB and BA.2, suggesting a high potential for immune evasion. JN.1 (BA.2.86.1.1), appeared in late 2023 after the format had undergone evolution. JN.1 carries three mutations in proteins that do not include S, as well as S: L455S. As previously demonstrated, the HK.3 and other “FLip” variations possess the S: L455F mutation, which enhances transmissibility and immune escape capacity in comparison to the parental EG.5.1 variety. This mutation is a characteristic of JN.1. The COVID-19 virus is dynamic and evolves over time. New varieties can sometimes spread more quickly or effectively after these alterations. If that happens, the new variant has a chance to outpace the current varieties in terms of frequency.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/iddt/10.2174/0118715265304215240530073446
2024-06-27
2025-01-11

  • From This Site

    /content/journals/iddt/10.2174/0118715265304215240530073446
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. MahaseE. COVID-19: New “Pirola” variant BA.2.86 continues to spread in UK and US.BMJ2023382p209710.1136/bmj.p2097 37704230
     [Google Scholar]
  2. VinallF NirappilF. New coronavirus variant JN.1 is spreading fast. Here’s what to know.2023Available from: post.com/wellness/2023/12/20/new-covid-variant-jn1-symptoms/(Last accessed on January 13, 2024).
  3. RoxbyP.J.N. 1 COVID variant: WHO charts its rapid global spread.BBC News2023Available from: https://www.bbc.co.uk/news/health-67772390(Last accessed on January 13, 2024).
     [Google Scholar]
  4. LooiM.K. COVID-19: WHO adds JN.1 as new variant of interest.BMJ2023383p297510.1136/bmj.p2975 38128957
     [Google Scholar]
  5. UriuK. ItoJ. KosugiY. Transmissibility, infectivity, and immune 172 evasion of the SARS-CoV-2 BA.2.86 variant.Lancet Infect. Dis.20232311173174
     [Google Scholar]
  6. WangQ. GuoY. LiuL. Antigenicity and receptor affinity of 175 SARS-CoV-2 BA.2.86 spike.Nature2023176
     [Google Scholar]
  7. ShewardD.J. YangY. WesterbergM. Sensitivity of the SARS-CoV-2 BA.2.86 variant to prevailing neutralising antibody responses.Lancet Infect. Dis.20232311e462e46310.1016/S1473‑3099(23)00588‑1 37776877
     [Google Scholar]
  8. YangS. YuY. JianF. Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86.Lancet Infect. Dis.20232311e457e45910.1016/S1473‑3099(23)00573‑X 37738994
     [Google Scholar]
  9. KosugiY. PlianchaisukA. PutriO. Virological characteristics of the 182 SARS-CoV-2 Omicron HK.3 variant harboring the “FLip” substitution.BioRxiv202310.1101/2023.11.14.566985
     [Google Scholar]
  10. KakuY. OkumuraK. Padilla-BlancoM. Virological characteristics of the SARS-CoV-2 JN.1 variant.Lancet Infect. Dis.2024S1473S3099
     [Google Scholar]
  11. YamasobaD. KimuraI. NasserH. Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike.Cell20221851221032115.e1910.1016/j.cell.2022.04.035 35568035
     [Google Scholar]
  12. UriuK. ItoJ. ZahradnikJ. Enhanced transmissibility, infectivity, and 187 immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant.Lancet Infect. Dis.2023233280281
     [Google Scholar]
  13. MukherjeeS. RayS.K. A new wave of COVID-19 in 2021 with unique genetic characters - Present global scenario and beholding onwards.Infect. Disord. Drug Targets2022226e01042220293210.2174/1871526522666220401101818 35366784
     [Google Scholar]
  14. MukherjeeS. RayS.K. Third wave of the COVID-19 pandemic: Prominence of initial public health interference.Infect. Disord. Drug Targets2022224e08022220091910.2174/1871526522666220208115101 35135456
     [Google Scholar]
  15. AltamimiI. AlabdulkarimI.M. AlhumimidiA.S. AlbabtainM.A. TemsahM.H. Navigating novel uncertainties of COVID-19: The rise of the JN.1 variant.Cureus2024161e5149710.7759/cureus.51497 38304689
     [Google Scholar]
  16. GISAID. Available from: https://gisaid.org/hcov19-variants/(Last accessed on January 13, 2024).
  17. PlanasD. StaropoliI. MichelV. LemoineF. DonatiF. ProtM. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86 lineages combined increased fitness and antibody evasion.bioRxiv202310.1101/2023.11.20.567873
     [Google Scholar]
  18. WangQ. GuoY. BowenA. MellisI.A. ValdezR. GherasimC. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants.bioRxiv202310.1101/2023.11.26.568730
     [Google Scholar]
  19. World health organization technical advisory group on COVID-19 vaccine composition.Available from: https://www.who.int/news/item/13-12-2023-statement-on-the-antigen-composition-of-covid-19-vaccines(Last accessed on January 13, 2024).
  20. World health organization technical advisory group on COVID-19 vaccine composition.Available from: https://www.who.int/news/item/18-05-2023-statement-on-the-antigen-composition-of-covid-19-vaccines (Last accessed on January 13, 2024).
  21. Executive Summary Executive Summary. WHO.Available from: https://www.who.int/docs/default-source/coronaviruse/18122023_jn.1_ire_clean.pdf?sfvrsn=6103754a_3 (Last accessed on January 13, 2024).
  22. EU4S-DEEP - Wastewater observatory for public health - Digital European exchange platform.Available from: https://wastewater-observatory.jrc.ec.europa.eu/#/gis-area/3(Last accessed on January 13, 2024).
  23. YangS. YuY. XuY. JianF. SongW. YisimayiA. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure.bioRxiv202310.1101/2023.11.13.566860
     [Google Scholar]
  24. Presentation at the WHO technical advisory group (TAG-VE) meeting on 11 December. Statens Serum Institut,Denmark2023
     [Google Scholar]
  25. Presentation at the WHO Technical Advisory Group (TAG-VE) meeting on 11 December. Ministry of Health,Singapore2023
     [Google Scholar]
  26. Variant proportions. CDC.2023Available from: https://covid.cdc.gov/covid-data-tracker/#variant(Last accessed on January 13, 2024).
  27. Initial risk evaluation of BA.2.86 and its sublineages.2023 Available from: https://www.who.int/docs/default source/coronaviruse/21112023_ba.2.86_ire.pdf?sfvrsn=8876def1_3(Last accessed on January 13, 2024).
  28. World Health Organization 2024 Available from: https://www.who.int/docs/default-source/coronaviruse/15042024_jn1_ure.pdf?sfvrsn=8bd19a5c_7
  29. RayS.K. MukherjeeS. From bench side to bed-travelling on a road to get a safe and effective vaccine against COVID-19, day to save the life.Recent Pat. Biotechnol.20221612510.2174/1872208315666211209094457 34886784
     [Google Scholar]
  30. RayS.K. MukherjeeS. Immunological facet and inception after post-COVID-19 vaccination.Infect. Disord. Drug Targets2023235e06042321549610.2174/1871526523666230406100146 37038664
     [Google Scholar]
  31. US centers for disease control and prevention. Variants happen. 2023Available from: https://www.cdc.gov/respiratory-viruses/whats-new/variants-happen.html (Last accessed on January 13, 2024).
/content/journals/iddt/10.2174/0118715265304215240530073446
Loading
Exploring New COVID-19 Incertitude: JN.1 Variant- JN.1: The Queer Bird among Omicron Sublineages
Infect. Disord. Drug Targets 25, E270624231369 (2025); https://doi.org/10.2174/0118715265304215240530073446
/content/journals/iddt/10.2174/0118715265304215240530073446
/content/journals/iddt/10.2174/0118715265304215240530073446
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): BA.2.86.1.1; COVID-19; FLip; JN.1; Omicron; SARS-CoV-2

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test